World Theatre to host Annual Animation Show of Shows Dec. 27-28 – Kearney Hub

KEARNEY Ron Diamond describes the 10 short animated films of the 21st Annual Animation Show of Shows as kid friendly, but also a bit tough and uncomfortable at times,

Diamond, founder and curator of the festival, calls the selection the best of the best animated short films, created by students and professionals around the world. The festival returns to theaters across North America and features 10 films from seven countries offering an array of highly imaginative, thought-provoking and moving works that reflect the filmmakers unique perspectives and their relationship to the world.

The 83-minute compilation will screen at 7:30 p.m. Dec. 27-28 and 2 p.m. Dec. 29 at The World Theatre, 2318 Central Ave. Admission is $5.

- Kids Michael Frei, Mario von Rickenbach, Switzerland

- Rubicon Gil Alkabetz, Germany

- Portrait of Gil Alkabetz (Rubicon) Marta Trela, Germany

- Five Minutes to Sea Natalia Mirzoyan, Russia

- Rcit de soi (Self-Narrative) Graldine Charpentier, Belgium

- Le jour extraordinaire (Flowing through Wonder) Joanna Lurie, France

- Hounds Amit Cohen, Ido Shapira, Israel

- Portrait of Amit Cohen and Ido Shapira (Hounds) Shlomi Yosef

- The Fox and the Bird (Le renard et loisille) Sam and Fred Guillaume, Switzerland

- Daughter Daria Kashcheeva, Czech Republic.

Personal relationships form the heart of several of the films in this years program, including Daria Kashcheevas International Student Academy Award-winning puppet animation Daughter, a deeply moving exploration of the ties between a father and daughter.

Charting a different, but related, course, The Fox and the Bird by Sam and Fred Guillaume is a beautifully observed fable about an unlikely friendship between the two eponymous characters. Filmmaker Michael Frei and game designer Mario von Rickenbach provide a more clinical view of human behavior in their mesmerizing Kids, which explores the nature of group dynamics.

Diamond said of the art form, Animation is an incredibly versatile medium that allows artists to explore situations and ideas that you wont see anywhere else. From political and philosophical concerns, to the complexities of individual identity and personal relationships, animated short films are uniquely able to capture the many facets of human experience.

Read more:
World Theatre to host Annual Animation Show of Shows Dec. 27-28 - Kearney Hub

Podcast: Latest discoveries in genetics, archaeology reveal early history of the British people – Genetic Literacy Project

Dr Kat Arney and the Genetics Unzipped team bring you not one but seven mini episodes to enjoy over the holidays. Recorded at the annual Galton Institute symposium New Light on Old Britons held at the Royal Society in London earlier this year, reporter Georgia Mills uncovers the latest research into the early history of the British people.

Who were these ancient Britons? Where did they come from and what were they like? Whats the real story behind the romantic myths about the Celts? And what can modern genetic and archaeological techniques tell us about their lives and loves?

Nick Ashton, an archaeologist at the British Museum and honorary professor at UCL, is studying the earliest humans in Europe.

Professor Ian Barnes and Dr Selina Brace, ancient DNA researchers at the Natural History Museum in London, discuss how their work on ancient DNA is shedding light on the British population from the Mesolithic to the Bronze Age.

Dr Silvia Bello from the Natural History Museum in London is investigating how patterns of human behavior have changed over the last million years.

Professor Sir Walter Bodmer from the Weatherall Institute, Oxford, explains what we know so far about genetic structure and origins of populations of the British Isles.

Dr Lara Cassidy from Trinity College Dublin talks about her work exploring the genomic history of Ireland.

The Celts are one of the most famous and misunderstood people who lived in ancient Britain. Professor Sir Barry Cunliffe from the University of Oxford explores the myths and the reality.

Professor Turi King from the University of Leicester reveals the secrets of the Y chromosome and how the remains of Richard III were identified.

Presented and produced by Georgia Mills for First Create The Media. Visit the Galton Institute website to find out more about the society, or follow them on Twitter @galtoninstitute

Genetics Unzippedis the podcast from the UKGenetics Society,presented by award-winning science communicator and biologistKat Arneyand produced byFirst Create the Media.Follow Kat on Twitter@Kat_Arney,Genetics Unzipped@geneticsunzip,and the Genetics Society at@GenSocUK

Listen to Genetics Unzipped onApple Podcasts(iTunes)Google Play,Spotify,orwherever you get your podcasts

Follow this link:
Podcast: Latest discoveries in genetics, archaeology reveal early history of the British people - Genetic Literacy Project

Instagram’s virtual features have real relationship benefits – WSU News

By Sara Zaske, WSUNews

PULLMAN,Wash. Young adults say that Instagram helps them develop friendships in real life, especially those who are more hesitant to try new experiences, according to a recent study by Washington State University researchers.

In the study published online in Computers in Human Behavior, the researchers analyzed survey responses of nearly 700collegeage adults about their perceptions and use of the socialmedia site.

The analysis found that the young adults liked how Instagram was easy to use as well as the many features of the highly visual platform. This encouraged them to express themselves on the socialmedia site, which in turn led to new and deeper relationships offline.

Our findings are optimistic: that selfdisclosure on Instagram could facilitate friendship development, even if followers were just casual acquaintances at the start, said Danielle Lee, the studys lead author and current doctoral student in WSUs EdwardR. Murrow College of Communication.

The results of the study suggested that Instagram had a greater effect on people who ranked low on the personality trait of openness, meaning they tend to be more reserved and closed to new experiences than those who ranked high in this trait.

Studies have shown that in general people who are not extroverted, who might be somewhat shy, find socialmedia platforms an easier way to interact with other people, said Associate Professor Porismita Borah, coauthor on the paper. Instagram is such a visually rich platform and that really helps in selfpresentation.

A large majority, 71%, of young Americans age18 to 24 use Instagram, according to a 2018 Pew Research Center survey. As the WSUstudy notes, users can

follow other people on Instagram without their approval, if their accounts are public, allowing for people to interact who dont have strong social ties outside of the platform. Instagram also distinguishes itself from other social networks with its focus on images: users cannot create a post without a visual as they can on Facebook and Twitter. The platform also provides easy ways to control how users present themselves.

In Instagram, you can change the image the way you want with filters and many different tools before posting it, said Borah. Both media richness and userfriendliness come together in Instagram, which is probably what makes it so appealing to the younger generation.

Go here to read the rest:
Instagram's virtual features have real relationship benefits - WSU News

The Growing Importance of Geopolitics in LL.M.s – LLM GUIDE

As the world becomes more volatile, uncertain, complex and ambiguous (VUCA), demand for legal advice is high. Some law schools have responded to messy, global challenges like Brexit and the US-China trade war by giving geopolitics much more prominence on the LL.M. syllabus.

The importance ofgeopoliticalaffairs is reflected in the teaching at Cardiff Universitys School of Law and Politics in Wales, UK. It runs a concentration in international affairs within its LL.M. course that explores a host of contemporary geopolitical challenges affecting the world today, from refugee law and asylum to money laundering and financial crime.

Recentgeopoliticalflashpoints provide us with contemporary case studies from which both the legal and political frameworks can be critically assessed, says program director Reece Lewis.

Because law and politics concern human behavior and affect relations between nations and peoples, geopolitical affairs are an essential element of LL.M. teaching, he says. It enables us to ask whether the present law or the political framework is fit for purpose and how our world could be better.

However, most law schools still include geopolitics as an optional elective module rather than creating fully fledged degrees in the subject. There are, however, a handful of specialized LL.M.s that might be relevant to students interested in geopolitics, such as the International Criminal Justice and Armed Conflict LL.M. at Nottingham University in the UK. Elsewhere, UCLA Law School runs an International Law LL.M., and the Geneva Academy offers an LL.M. in International Humanitarian Law and Human Rights.

Some law schools argue that geopolitics is ingrained in nearly every subject they teach rather than being siloed as its own topic.

Basil Germond is the director of research training for the faculty of arts and social sciences at the UKs University of Lancaster, which has a law school. He argues that schools should not teachgeopolitics itself; rather they should teach students how to critically assess the importance of geopolitics to explain states actions on the world stage.

He argues that developments in international law must be applied to geopolitical realities, from the discovery of exploitable natural resources in contested maritime spaces, to changes in the regional balance of power.

It is thus crucial for LL.M. students to engage with the political and geographical dimensions of international relations, so as to be in a position to understand and critically assess the strengths and weaknesses of international law, he says.

In addition, another factor behind the rise in geopolitics in LL.M.s is the growing emphasis placed on interdisciplinarity in graduate education, Germond says, explaining that geopolitical courses often encompass law and politics faculty.

On the LL.M. programs at University of Bristol Law School in the UK, students not only explore case studies but can pursue geopolitics through independent research in their dissertations. In addition, geopolitical developments strongly inform the content of modules across the range of LL.M. programs the school offers. These courses include world trade, maritime security, public and global health law.

There are also new LL.M. concentrations that are designed to address geopolitical issues: international law and international relations; and law and globalization. Students undertaking these programmes will explore issues at the cutting-edge of law andgeopolitics, says Keith Syrett, LL.M. director. Bristol has always sought to take an approach to the teaching of law which situates legal norms and principles within a social, economic and political context.

Syrett says the increased focus on geopolitics at law schools reflects the growing number of academic staff working on issues at the interface between geopolitics and law. Those staff are eager to share their knowledge and ideas with a new generation of postgraduates, he adds.

But the subject can be hard to teach because of its breadth and complexity. And the diversity of students on LL.M. courses usually means that instructors have to be aware of cultural sensitivities to geopolitical issues.

Also, Lancasters Germond says that not all LL.M. students are aware of the importance of geopolitics. This needs to be communicated by program directors, he says.

But he notes that the growth in teaching of geopolitics on LL.M. programs is being driven by students career outcomes, even if some are not aware of its importance. Students of international law are likely to work in an environment where their understanding of international politics andgeopoliticsis as important as their knowledge of the very rules of international law, he says, like multinational corporations.

Indeed, geopolitics is not an industry, but graduates with a firm grasp of geopolitics may not only work in law, but in the public sector too, for example in global politics. Others work at NGOs.

With the world looking like an increasingly uncertain place, all industries may have need of geopolitically savvy lawyers in the near future.

Follow this link:
The Growing Importance of Geopolitics in LL.M.s - LLM GUIDE

The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping – BioSpace

SOUTH SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation(NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that The University of Michigan Protein Assembly Lab, a hub for collaborative and innovative research at the intersection of synthetic biology, protein engineering and personalized medicine, has chosen the Hyperion Imaging System to expand its capabilities in multiparameter imaging and immune profiling of tissue.

Building upon important research enabled by mass cytometry since 2016, the lab acquired a Hyperion Imaging System to expand its capabilities in multiparameter spatial analysis of the tissue microenvironment.

The Protein Assembly Lab is under the direction of Fei Wen, PhD, Associate Professor and Associate Chair for Undergraduate Education in Chemical Engineering, Director of the UM Mass Cytometry Core and Co-Director of the Immune Monitoring Shared Resource at the UM Rogel Cancer Center.

Our lab is exploring novel ways to push the field of precision health forward by engineering multiple protein assemblies into single entities that can act in an orchestrated and synergistic manner to carry out specific and sophisticated immunological functions to treat cancer and autoimmune disorders and to prevent viral infections, said Wen. We believe this approach could contribute to advances in a number of areas, including synthetic biology, cancer immunotherapy and immune phenotyping.

The Hyperion Imaging System enables us to extract a wealth of useful information from limited patient biopsy samples, which is critical to understanding patient-to-patient variability and developing novel and precise diagnostic and therapeutic reagents, Wen said.

Mass cytometry deeply profiles immune cell phenotypes and functions and is the basis of more than 900 research publications documenting workon the frontiers of immunology, immuno-oncology and other realms of health and disease. The addition of the Hyperion Imaging System extends the use of mass cytometry and is revolutionizing high-multiplex tissue analysis by deeply characterizing the tumor microenvironment with an efficient one-scan workflow.

We are truly excited that the University of Michigan Protein Assembly Lab has chosen the Hyperion Imaging System for critical research in a range of key areas including cancer immunotherapy and immune phenotyping, saidChris Linthwaite,FluidigmPresident and CEO. The University of Michigan is ranked number one in research volume among all U.S. public universities, and this is yet another example of the increasing adoption of our technology by premiere academic medical centers that are pioneering disease and therapy research innovation.

This commitment by the university also demonstrates the power of expanding research capabilities to include both suspension and imaging-based technology for more comprehensive analysis, supporting work with the potential to change the face of medicine, Linthwaite said.

About Fluidigm

Fluidigm(NASDAQ:FLDM) is an industry-leading biotechnology toolsprovider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, the Fluidigm logo, CyTOF, Hyperion, and Imaging Mass Cytometry are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding prospects for Fluidigm mass cytometry and Imaging Mass Cytometry products and the potential benefits of such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigms Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

Contacts:

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

Media: Michaeline BuntingSenior Director, Marketing650 737 4190michaeline.bunting@fluidigm.com

See the original post here:
The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping - BioSpace

Bondada Named Fellow of the American Association for the Advancement of Science – UKNow

LEXINGTON, Ky. (Dec. 16, 2019) Subbarao Bondada, professor of microbiology in the Department of Microbiology,Immunology and Molecular Genetics in the University of Kentucky College of Medicine and Markey Cancer Center, has beennamed a Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers.

Bondada is being recognized for distinguished contributions to the field of immunology, particularly to studies of biology of normal and malignant B lymphocytes and antibody responses to bacterial polysaccharide antigens.

This year 443 members have been awarded this honor by AAAS because of their scientifically or socially distinguished efforts to advance science or its applications. New Fellows will be presented with an official certificate and a gold and blue (representing science and engineering, respectively) rosette pin on Saturday, Feb. 15at the AAAS Fellows Forum during the 2020 AAAS Annual Meeting in Seattle, Washington.

The tradition of AAAS Fellows began in 1874. Currently, members can be considered for the rank of Fellow if nominated by the steering groups of the associations 24 sections, or by any three Fellows who are current AAAS members (so long as two of the three sponsors are not affiliated with the nominees institution), or by the AAAS chief executive officer. Fellows must have been continuous members of AAAS for four years by the end of the calendar year in which they are elected. The AAAS Fellow honor comes with an expectation that recipients maintain the highest standards of professional ethics and scientific integrity.

Each steering group reviews the nominations of individuals within its respective section and a final list is forwarded to the AAAS Council, which votes on the aggregate list.

The Council is the policymaking body of the Association, chaired by the AAAS president, and consisting of the members of the board of directors, the retiring section chairs, delegates from each electorate and each regional division, and two delegates from the National Association of Academies of Science.

AAAS encourages its sections and Council to consider diversity among those nominated and selected as Fellows, in keeping with the associations commitment to diversity, equity and inclusion.

Visit link:
Bondada Named Fellow of the American Association for the Advancement of Science - UKNow

Cracking the Fever-Autism Mystery – Harvard Medical School

For many years, the parents of children with autism have reported that behavioral symptoms diminished when the child had a fever. The fever phenomenon has been documented in at least two large-scale studies over the past 15 years, but the reasons behind it have continued to mystify scientists.

Now, a new study by researchers at Harvard Medical School and MIT sheds light on the cellular mechanisms that appear to underlie this phenomenon.

In a study of mice, published Dec. 18 inNature, the researchers found that in some cases mimicking bacterial infection, an immune molecule called IL-17a is released and suppresses a small region of the brains cortex linked to social behavioral deficits in animal models.

Our findings finger the signaling cascade that leads to temporary alleviation of autism-like symptoms upon exposure to inflammatory conditions, highlighting the complex interplay between the nervous and immune systems in neurodevelopmental disorders such as autism, said study co-corresponding authorJun Huh, assistant professor of immunology in the Blavatnik Institute at HMS.

People have seen this phenomenon before [in people with autism], but its the kind of story that is hard to believe, which I think stems from the fact that we did not know the mechanism, saidGloria Choi, the Samuel A. Goldblith Career Development Assistant Professor of Applied Biology and an assistant professor of brain and cognitive sciences at MIT. Now the field, including my lab, is trying hard to show how this worksall the way from the immune cells and molecules to receptors in the brainand how those interactions lead to behavioral changes.

Although findings in mice do not always translate into humans, the study may help guide the development of strategies that could help reduce some behavioral symptoms of autism or other neurologic disorders, said Choi, who is also a faculty member of MITs Picower Institute for Learning and Memory.

The lead authors of the research are MIT graduate student Michael Douglas Reed and MIT postdoctoral fellow Yeong Shin Yim.

Immune influence

Choi and Huh previously explored other links between inflammation and autism. In 2016,they showedthat mice born to mothers who experience severe infections during pregnancy are much more likely to show behavioral symptoms such as deficits in sociability, repetitive behaviors and abnormal communication. They found these symptoms stem from exposure to maternal IL-17a, which produces defects in a specific brain region of the developing embryo. The brain region, S1DZ, is part of the somatosensory cortex and believed to be responsible for sensing where the body is in space.

Immune activation in the mother leads to very particular cortical defects, and those defects are responsible for inducing abnormal behaviors in offspring, Choi said.

A link between infection during pregnancy and autism in the offspring has also been documented in humans. A 2010 study that included children born in Denmark between 1980 and 2005 found that severe viral infections during the first trimester of pregnancy led to a threefold increase in risk for autism, and serious bacterial infections during the second trimester were linked with a 1.42-fold increase in risk. These infections included influenza, viral gastroenteritis and severe urinary tract infections.

In the new study, Choi and Huh turned their attention to the often-reported link between fever and reduction of autism symptoms.

We wanted to ask whether we could use mouse models of neurodevelopmental disorders to recapitulate this phenomenon, Choi said. Once you see the phenomenon in animals, you can probe the mechanism.

The researchers began by studying mice that exhibited behavioral symptoms due to exposure to inflammation during gestation. They injected these mice with a bacterial component called LPS, which induces a fever response, and found that the animals social interactions were temporarily restored to normal.

Further experiments revealed that during inflammation these mice produce IL-17a, which binds to receptors in S1DZthe same brain region shown to be affected by maternal inflammation. The experiments showed that IL-17a reduces neural activity in S1DZ, making mice temporarily more interested in interacting with fellow mice.

When researchers inhibited IL-17a or knocked out the receptors for IL-17a, mice did not experience a reversal of symptoms, a finding that pinpointed IL-17a as the responsible trigger. The experiments also showed that simply raising mices body temperature did not have any effect on behavior, offering further evidence that IL-17a is, indeed, the critical player behind reversal of symptoms.

This suggests that the immune system uses molecules like IL-17a to directly talk to the brain, and it actually can work almost like a neuromodulator to bring about these behavioral changes, Choi said. Our study provides another example as to how the brain can be modulated by the immune system.

Whats remarkable about this paper is that it shows that this effect on behavior is not necessarily a result of fever but the result of cytokines being made, said Dan Littman, the Helen L. and Martin S. Kimmel Professor of Molecular Immunology at New York University, who was not involved in the study. Theres a growing body of evidence that the central nervous system, in mammals at least, has evolved to be dependent to some degree on cytokine signaling at various times during development or postnatally.

Behavioral effects

The researchers then performed the same experiments in three additional mouse models of neurologic disorders. These mice lack a gene linked to autism and similar disorderseitherShank3,Cntnap2orFmr1. These mice all show deficits in social behavior similar to those of mice exposed to inflammation in the womb, even though the origin of their symptoms is different.

Injecting those mice with LPS did produce inflammation, but it did not have any effect on their behavior. The reason for that, the researchers found, is that in these mice, inflammation did not stimulate IL-17a production. However, if the researchers injected IL-17a into these mice, their behavioral symptoms did improve.

This suggests that mice who are exposed to inflammation during gestation end up with their immune systems somehow primed to more readily produce IL-17a upon exposure to other inflammatory conditions later in their life. Choi and Huh havepreviously shownthat the presence of certain bacteria in the gut can also prime IL-17a responses. They are now investigating whether the same gut-residing bacteria contribute to the LPS-induced reversal of social behavior symptoms that they found in the newNaturestudy.

Huh and Chois labs are also exploring whether any immune molecules other than IL-17a may affect the brain and behavior.

Whats fascinating about this communication is the immune system directly sends its messengers to the brain, where they work as if theyre brain molecules, to change how the circuits work and how the behaviors are shaped, Choi said.

It was amazing to discover that the same immune molecule, IL-17a, could have dramatically opposite effects depending on context: Promoting autism-like behaviors when it acts on the developing fetal brain and ameliorating autism-like behaviors when it modulates neural activity in the adult mouse brain, Huh said. This is the degree of complexity we are trying to make sense of.

The research was funded by the Jeongho Kim Neurodevelopmental Research Fund, Perry Ha, the Hock E. Tan and K. Lisa Yang Center for Autism Research, the Simons Center for the Social Brain, the Simons Foundation Autism Research Initiative, the Champions of the Brain Weedon Fellowship, and a National Science Foundation Graduate Research Fellowship.

Adapted from an MITnews release

Read more:
Cracking the Fever-Autism Mystery - Harvard Medical School

Strategic Assessment of Infectious Immunology Provides in-depth Analysis of Global Market 2019-2024 Poised to Expand at Progressive Rate | Top Players…

HealthCare Intelligence Markets has published a new report titled Infectious Immunology Market. Infectious Immunology involves studies of how the immune system responds to infectious agents and how infectious agents interact, modify or prevent the immune system. In recent years, there have been important advances in our understanding of the immune response to infection.

In order to provide an effective business outlook various global region such as North America, Latin America, Asia-Pacific, Europe and India have been examined. Major Key parameter of the businesses like profit margin, market shares and pricing structures have also been studied closely. To offer a clear understanding of Infectious Immunology Market various questions have been addressed in this analytical study concerning the progress of the businesses.

Ask for sample copy of this report at @ https://healthcareintelligencemarkets.com/request_sample.php?id=134517

Top Players profiled in this report Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientifics, Bio-Rad Laboratories, Dr. Reddys Laboratories and many more.

Primary and Secondary research methodologies have been used to scrutinize the different aspects of the businesses. In addition to this, it offers facts and figures on productivity across the various leading key players. Different influencing factors, which are driving or restraining the growth of the businesses have been studied to understand its upstream and downstream. Technological frameworks and effective tools are listed to give a clear approach to boost the performance of the companies.

Get Expected Discount on this report @ https://healthcareintelligencemarkets.com/ask_for_discount.php?id=134517

This statistical survey report offers numerous approaches to discover global opportunities for the rapid expansion of the business. It gives a comprehensive analysis of the Infectious Immunology Market which calculates different verticals of businesses such as, production capacity, local consumers, global and local clients and potential customers.

Furthermore, this research report has been aggregated on the basis of reliable analysis of dynamic aspects of the businesses. It presents a comparative analysis of Infectious Immunology companies to get extract information on resources and their effective utilization to achieve the desired outcome.

Table of Contents

Chapter 1 Infectious Immunology Market Overview

Chapter 2 Economic Impact on Industry

Chapter 3 Market Competition by Manufacturers

Chapter 4 Production, Revenue (Value) by Region

Chapter 5 Supply (Production), Consumption, Export

Chapter 6 Production, Revenue (Value), Price Trend by Type

Chapter 7 Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Market Forecast

Lastly, this report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market.

For more information ask our experts @ https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=134517

If you have any special requirements, please let us know and we will offer you the report as per your requirements.

About HealthCare Intelligence Markets

90 State Office Center,

90 State Street Suite 700, Albany,

NY 12207

sales@healthcareintelligencemarkets.com

+1 (888) 616-2766

Read more:
Strategic Assessment of Infectious Immunology Provides in-depth Analysis of Global Market 2019-2024 Poised to Expand at Progressive Rate | Top Players...

Jeffrey Goldberg Appointed Chief Executive Officer and Director of Immunitas Therapeutics – BioSpace

One of the central challenges of drug development has been bridging the gap between laboratory research in model organisms to meaningful clinical advances in humans, said Jeff Goldberg. Immunitas and our scientific co-founders use single cell genomic sequencing and sophisticated computational biology techniques to look at human biology directly. I believe this innovative approach can help to accelerate the development of new therapies for patients. I am excited to be joining the Immunitas team as we discover and develop these highly targeted new immuno-oncology therapies.

Immunitas identifies novel, promising oncology targets with potential applicability across both solid and liquid tumors. Additionally, as part of the discovery process, Immunitas develops key biomarkers to guide the selection of patients who may benefit from its new drugs. The company leverages its expertise in antibody discovery and engineering to create therapies that modulate these targets. Immunitas is currently advancing a number of programs toward early human studies, including a lead program with fully-human monoclonal antibodies that will be developed as single agents using a clinical biomarker strategy to guide early efficacy studies.

Jeff Goldberg has over 20 years of industry experience driving programs from discovery through all phases of drug development to commercialization in multiple therapeutic areas, including oncology, neurology, renal, and rare diseases, said Lea Hachigian, President and Director, Immunitas Therapeutics. We are fortunate to have his demonstrated ability leading and building teams as we create an oncology company powered by our human biology-focused approach to immunology.

Mr. Goldberg joins the Immunitas Board of Directors, which includes Dr. Laura Brass, Managing Director at Novartis Venture Fund, Dr. Jrgen Eckhardt, Head of Leaps by Bayer, Bayers strategic venture capital unit, Dr. Lea Hachigian, Principal, Longwood Fund, Dr. Lucio Iannone, Director of Venture Investments of Leaps by Bayer, Dr. Christoph Westphal, co-founder and General Partner of Longwood Fund, and Dr. Vincent Xiang, Managing Director at Hillhouse Capital.

Jeff Goldberg is an experienced biotech program and brand leader with over 20 years of industry experience. He has driven programs from discovery and pre-clinical through IND, clinical trials, NDA, and commercialization in multiple therapeutic areas, including oncology, neurology, renal, and other rare and orphan diseases. Mr. Goldberg joins Immunitas from Akcea Therapeutics, where he was Chief Operating Officer from the time of its formation in January 2015. Previously, Mr. Goldberg was VP of Business Operations, leading both program management and business development at Proteostasis Therapeutics, Inc., a biotech company focusing on neurology and rare diseases. He also spent more than 11 years in positions of increasing responsibility with Genzyme and Sanofi, providing brand management for two marketed products within Sanofi Oncology. Prior to joining Sanofi Oncology, Mr. Goldberg served as Global Program Lead for Genzyme's stem cell mobilization agent Mozobil, leading the global launch team and overseeing the program management and marketing functions for the product. He began his career at Genzyme as Director, Program Management overseeing the development and launch of Renvela in patients undergoing dialysis. Mr. Goldberg has both an MBA and a Master's degree in Chemical Engineering from the Massachusetts Institute of Technology, and a B.S. in Chemical Engineering from Cornell University.

About Immunitas Therapeutics

Immunitas Therapeutics, founded by Longwood Fund, employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and greatly accelerates the pace of our research. The Immunitas team of scientific pioneers innovates around each step of the drug development process, first identifying novel targets, then designing therapeutic strategies, and developing key biomarkers to guide the selection of patients who may benefit from our new drugs. Lead programs from this platform have demonstrated single agent activity against challenging tumors and fully-human monoclonal antibodies are advancing towards clinical studies. http://www.ImmunitasTx.com.

Immunitas the human approach to oncology

View source version on businesswire.com: https://www.businesswire.com/news/home/20191218005153/en/

Excerpt from:
Jeffrey Goldberg Appointed Chief Executive Officer and Director of Immunitas Therapeutics - BioSpace

Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company’s Tyk2 Subsidiary – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company coupling targets selected based on causal human biology with structure-based drug discovery and development, today announced the promotion of Chief Medical Officer, Annie C. Chen, M.D., MPH, to President of the companys Tyk2 subsidiary, Nimbus Lakshmi, Inc. In this role, Dr. Chen will provide executive leadership for financial, business, and development activities associated with the companys tyrosine kinase 2 (Tyk2) program, in addition to continuing her role as Chief Medical Officer for Nimbus Therapeutics.

Were at a very exciting juncture as Nimbus gears up to once again become a clinical-stage company, and there is no better person to helm that effort than Annie, said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. Annies extensive background in immunology, her experience leading clinical strategy to bring multiple therapies forward to regulatory approval, and her passionate dedication as a clinician to the well-being of her patients will be of enormous value to our Tyk2 program as it advances into the clinic.

Tyk2 is a genetically validated target for the treatment of many autoimmune and inflammatory disorders, and through Nimbus structure-based drug discovery efforts, we have developed promising allosteric modulators that effectively inhibit this target, said Dr. Chen. Im honored to lead these multidisciplinary efforts for Nimbus as we initiate clinical studies and chart the programs future path.

Dr. Chen, who received her medical training as an adult rheumatologist, has served as Chief Medical Officer of Nimbus since 2015. She provided oversight for the companys acetyl CoA carboxylase clinical program for NASH and supported business development and financing efforts, before its acquisition by Gilead. Prior to joining Nimbus, Dr. Chen was Executive Director of Clinical Research, Section Head of Vaccines at Merck and Co., where she oversaw clinical research activities for a broad portfolio of vaccines, from discovery through registration and life cycle management. Dr. Chen also held the role of Section Head of Immunology, where she oversaw clinical research for small molecule and protein therapeutics. Prior to Merck, Dr. Chen held roles of increasing responsibility at Genentech, and began her career at Celera Genomics.

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and that have proven difficult for other drug makers to tackle. The companys LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. For more information, please visit http://www.nimbustx.com.

Read more here:
Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company's Tyk2 Subsidiary - Business Wire